Sangamo Therapeutics
Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.
-
Gene-Editing breakthrough? early trial tackles sickle cell at its root
Disease control CompletedThis early-stage study tested a new gene-edited stem cell treatment (BIVV003) in 7 adults with severe sickle cell disease. The goal was to see if the treatment is safe and can help the body make healthy red blood cells. Participants received their own genetically modified stem ce…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated May 26, 2026 06:17 UTC
-
One-Time gene therapy could change fabry disease treatment
Disease control CompletedThis study tested a new gene therapy called ST-920 for people with Fabry disease, a rare genetic condition. The therapy uses a harmless virus to deliver a working gene that helps the body produce an enzyme it's missing. 36 adults received a single intravenous dose and were follow…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC